SCHEMBL1860622

SCHEMBL1860622

CCCCN(C[C@@H](N)CC1CCCCC1)C(=O)OCC[Si](C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.38
REN P00797 2/20 0.36
BDKRB2 P30411 2/20 0.33
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32
GPR88 Q9GZN0 1/20 0.32
CTSK P43235 2/20 0.32
CTSL P07711 1/20 0.32
CTSB P07858 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
EPHX2 P34913 1/20 0.31
BCHE P06276 2/20 0.31
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27709482 1.00 METAP2 (0.38) METAP2RENBDKRB2ALDH1A1KMT2A
SCHEMBL1863823 0.97 METAP2 (0.39) METAP2RENBDKRB2ALDH1A1KMT2A
SCHEMBL1862541 0.93 METAP2 (0.34) METAP2RENGPR88CTSKCTSL
SCHEMBL3612224 0.89 GPR88 (0.34) METAP2RENGPR88CTSK
SCHEMBL1868000 0.89 GPR88 (0.34) METAP2RENGPR88CTSK
SCHEMBL1864029 0.88 GPR88 (0.32) METAP2RENGPR88CTSKCTSL
SCHEMBL1864027 0.88 GPR88 (0.32) METAP2RENGPR88CTSKCTSL
SCHEMBL1867741 0.88 CTSK (0.33) METAP2RENGPR88CTSKCTSL
SCHEMBL1863146 0.85 CTSK (0.34) METAP2RENGPR88CTSKCTSL
SCHEMBL1863912 0.84 GPR88 (0.33) METAP2GPR88CTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed
US-7754737-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-07-13 US disclosed
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors VITAE PHARMACEUTICAL, INC (US) 2009-01-15 US disclosed
EP-1807078-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed
WO-2006042150-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE METAP2 44/4885REN 298/4885BDKRB2 420/4885
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors DNPEP, PEPD, ACE METAP2 44/4885REN 298/4885BDKRB2 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.